Dr. Panteli Theocharous

Doctor Theocharous currently serves as Chief Therapeutics Officer at Garuda Therapeutics, Inc., a company creating off-the-shelf, durable blood stem cell-based cellular therapies. As a senior-level industry executive in prior C-Suite roles and a cancer immunotherapy expert, Dr. Theocharous brings extensive experience in clinical development in malignant hematological disorders (importantly in Multiple Myeloma), Patient Advocacy Group partnerships, as well as global regulatory and payer submission strategy development. Specifically, Dr. Theocharous led development of first-generation clinical CAR-T, novel cell therapy applications in malignant diseases, and gene-directed therapies in benign disorders.

More recently, Dr. Theocharous served as the Global Head, Cell and Gene Therapy Strategy Lead at PPD, part of Thermo Fisher Scientific. Prior to PPD, Dr. Theocharous held global Clinical and Medical Affairs leadership roles at Cell Therapeutics Inc. and Janssen Oncology, and was Director for Stem Cell Transplantation and Advanced Therapies at the Royal Free Hospital in London. In the clinical arena, Dr. Theocharous worked with Professor A. Victor Hoffbrand in hematologic disorders and under mentorship by Professor H. Grant Prentice in hematopoietic stem cell transplantation. Dr. Theocharous received an MS in applied clinical hematology, and cancer medicine related higher degrees from the Royal Free and University College Medical School at the University of London. Dr. Theocharous has a successful track record of significant executive-level client consultation and strategic advisement including leadership and influence at CEO and biotech board level.